Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Warner

Vascular Surgery Midlothian, VA Medical Doctor

NPI 1679569230 CMS profile 212051

13460 Tredegar Lake Pkwy, Midlothian, VA 23112

Open in the dashboard

General payments

$17,351

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Warner of Midlothian, VA is reported in the CMS Open Payments database as having received $17,351 across 71 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $684 10
2024 General $2,208 8
2023 General $8,314 20
2022 General $4,995 12
2021 General $520 12
2020 General $480 7
2019 General $150 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Warner
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Marc Warner were reported at $684. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Marc Warner Vascular Surgery median Middle half National median
2019 $150 $796 $226–$2,363 $163
2020 $480 $348 $118–$1,110 $114
2021 $520 $471 $158–$1,421 $132
2022 $4,995 $725 $222–$2,183 $149
2023 $8,314 $836 $257–$2,440 $160
2024 $2,208 $909 $252–$2,619 $164
2025 $684 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $13,833 6 payments
  2. Medtronic, Inc. $1,312 27 payments
  3. Silk Road Medical, Inc. $404 3 payments
  4. Medtronic Vascular, Inc. $399 6 payments
  5. Shockwave Medical, Inc $361 2 payments
  6. Abbott Laboratories $174 2 payments
  7. Penumbra, Inc. $162 3 payments
  8. Philips Electronics North America Corporation $151 3 payments
  9. Janssen Pharmaceuticals, Inc $109 6 payments
  10. Inspire Medical Systems, Inc. $82 1 payment
  11. Other $363 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $13,833 6 payments
  2. Food and Beverage $3,518 65 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $13,833 6 payments
  2. ENDURANT IIS $952 14 payments
  3. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $256 2 payments
  4. ENROUTE Transcarotid Stent $256 2 payments
  5. Valiant Navion $230 3 payments
  6. Endurant Aortic Stent Grafts $226 5 payments
  7. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $185 1 payment
  8. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $176 1 payment
  9. Endurant Aortic Stent Grafts $169 3 payments
  10. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $148 1 payment
  11. Other $1,842 39 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

154

Median for Vascular Surgery: 122

Drug cost

$10,906

Median for Vascular Surgery: $14,135

Branded share of claims

87%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $9,935
Clopidogrel Clopidogrel Bisulfate Brand 44 $487
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 77 $367
Oxycodone Hcl Generic 20 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 126 billing codes

Paid by Medicare

$491,895

Of which drugs: $122

Medicare patients

1,301

Average age 76

Services billed

2,677

679 women, 622 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Chronic kidney disease 44%
Ischemic heart disease 43%
Diabetes 42%
Heart failure 30%
Atrial fibrillation 26%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, fentanyl citrate, 0.1 mg J3010 Office 33 42 $32
Injection, midazolam hydrochloride, per 1 mg J2250 Office 43 100 $11

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record